Semaglutide Lyophilized Powder 10mg

Semaglutide Lyophilized Powder 10mg for Diabetes and Weight Loss

• A once-weekly subcutaneous injection for improving blood sugar and weight management
• Initial dose: Typically 0.25 mg once weekly
• Dose escalation: Gradual increases from 0.25 mg can minimize side effects
• Dosage form: Reconstitutes to a practical concentration for accurate dosing, with a maximum of 3 ml available
• Storage: Store lyophilized powder frozen; after reconstitution, refrigerate
• Semaglutide is a long-acting GLP-1 (glucagon-like peptide-1) receptor agonist developed for the management of type 2 diabetes mellitus (T2DM) and obesity. It enhances glucose-dependent insulin secretion, delays gastric emptying, and reduces appetite, resulting in improved glycemic control and significant weight reduction.
  This product is supplied as a 10 mg lyophilized sterile powder in vials, which must be reconstituted with bacteriostatic water before administration. Clinical studies demonstrate that semaglutide provides superior weight loss efficacy compared to earlier GLP-1 receptor agonists, making it a leading therapeutic option in metabolic disease management.
  Key Benefits
  Glycemic Control
  • Stimulates insulin secretion in a glucose-dependent manner
  • Suppresses glucagon secretion, lowering hepatic glucose output
  • Improves HbA1c and fasting plasma glucose
  Weight Management
  • Strong appetite suppression and enhanced satiety
  • Progressive and clinically meaningful weight loss
  • FDA-approved up to 2.4 mg for obesity management
  Metabolic & Cardiovascular Health
  • Improves lipid metabolism and reduces triglycerides
  • Demonstrated cardiovascular risk reduction in T2DM patients
  • Potential benefits in liver fat reduction (NAFLD/NASH)
  Usage and Dosage
  Semaglutide lyophilized powder should be reconstituted with bacteriostatic water prior to injection. Administration is via subcutaneous injection once weekly, ideally on the same day each week.
  Type 2 Diabetes & Obesity (Unified Protocol)
  • Starting Dose: 0.25 mg once weekly
  • Titration: Increase every 4 weeks as tolerated (→ 0.5 mg → 1.0 mg → 1.7 mg → 2.4 mg)
  • Common Dose: 1.0–2.0 mg weekly
  • Maximum Dose: 2.4 mg weekly
  Recommended Dosage Table

  Indication	Starting Dose	Titration Schedule	Common Dose	Maximum Dose	Frequency
  Type 2 Diabetes / Obesity	0.25 mg weekly	Every 4 weeks (→ 0.5 → 1.0 → 1.7 → 2.4 mg)	1.0–2.0 mg weekly	2.4 mg weekly	Once weekly

  Possible Adverse Reactions
  • Gastrointestinal: nausea, vomiting, diarrhea, abdominal pain (especially during titration)
  • Hypoglycemia: low risk alone; higher when combined with insulin or sulfonylureas
  • Injection Site Reactions: redness, itching, swelling, or mild pain
  • Pancreatitis: rare cases reported; monitoring advised
  • Gallbladder Disorders: possible increased risk of gallstones
  • Heart Rate: mild increase observed in some patients
  Pharmacokinetics
  • Half-Life: ~7 days
  • Dosing Interval: supports once-weekly injection
  • Metabolism: proteolytic degradation; not primarily renal-dependent
  Summary
  Semaglutide 10 mg lyophilized powder is a once-weekly GLP-1 receptor agonist for the treatment of T2DM and obesity. Starting at 0.25 mg weekly and titrated up to 2.4 mg, it provides:
  • Potent glycemic control
  • Clinically significant weight loss
  • Metabolic and cardiovascular benefits
  It represents a well-established and effective therapeutic option for patients seeking long-term metabolic health improvement.